GlassScriptPhysician profile
Tyler C Howard
NPI 1043313166
$1,711.37
in general payments reported to CMS, 2019-2025
26 companies · $779 in 2025
The $779 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.24 · 2022: $180 · 2023: $439 · 2024: $257 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,476.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $254.09 | 2021-2025 | |
| Kestra Medical Technology Services, INC. | $155.43 | 2023-2025 | Assure Wcd |
| Novo Nordisk INC | $131.12 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Impulse Dynamics (USA) INC. | $117.26 | 2023 | Optimizer |
| Boston Scientific Corporation | $115.45 | 2024-2025 | Watchman Flx |
| Abbott Laboratories | $114.59 | 2022-2025 | Triclip, Cardiomems, Gallant |
| Alnylam Pharmaceuticals INC. | $99.40 | 2024-2025 | Onpattro |
| Angiodynamics, INC. | $98.85 | 2025 | Auryon Laser System 100-120 Vac |
| Merck Sharp & Dohme LLC | $90.68 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.88 | 2023-2025 | Jardiance |
| Amgen INC. | $61.99 | 2023 | Repatha |
| Scpharmaceuticals INC. | $53.04 | 2024-2025 | |
| Penumbra, INC. | $42.46 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $36.57 | 2022-2025 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $35.51 | 2024-2025 | Camzyos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $34.46 | 2023-2024 | Farxiga |
| Glaxosmithkline, LLC. | $33.49 | 2025 | Arexvy, Shingrix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.73 | 2025 | Lifevest |
| Siemens Medical Solutions USA, INC. | $24.49 | 2022 | |
| Heartflow, INC. | $22.21 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.20 | 2025 | |
| Lilly USA, LLC | $17.68 | 2025 | Zepbound |
| Medtronic, INC. | $16.51 | 2022 | |
| Pfizer INC. | $16.09 | 2025 | |
| Abiomed | $14.91 | 2025 | |
| Cook Medical LLC | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.